[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354686-105":59,"doc-detail-354686-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","non-coding-rnas-related-to-pd1pd-l1-signaling-with-potential-diagnostic-prognostic-and-therapeutic-value-in-the-tumorigenesis-of-brain-cancers","Non-coding RNAs related to PD1/PD-L1 signaling with potential diagnostic, prognostic, and therapeutic value in the tumorigenesis of brain cancers","","Brain cancers are among the most aggressive malignancies associated with significant global morbidity and mortality. Cancer immunotherapy has emerged as a promising novel approach for the treatment of brain cancer through regulating the PD-1/PD-L1 signaling and disrupting tumor immune escape. Several targeted therapies have been developed, yet reduced responses and drug resistance persist. Non-coding RNAs, including microRNAs, circular RNAs, and long non-coding RNAs, modulate proliferation, invasion, and immune escape in the tumor microenvironment, offering diagnostic, prognostic, and therapeutic opportunities.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/non-coding-rnas-related-to-pd1pd-l1-signaling-with-potential-diagnostic-prognostic-and-therapeutic-value-in-the-tumorigenesis-of-brain-cancers/354686/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/non-coding-rnas-related-to-pd1pd-l1-signaling-with-potential-diagnostic-prognostic-and-therapeutic-value-in-the-tumorigenesis-of-brain-cancers/354686.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does PD-1/PD-L1 signaling contribute to immune evasion in brain cancer?","Question",{"text":112,"@type":113},"PD-1 and its ligand PD-L1 initiate immunosuppressive pathways that help cancer cells avoid immune surveillance. PD-1 signaling dampens T-cell activation and can enhance tumor immune escape in the brain tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What types of non-coding RNAs are discussed in relation to PD-1/PD-L1?",{"text":117,"@type":113},"The review highlights microRNAs, circular RNAs, and long non-coding RNAs. These ncRNAs influence cell proliferation, invasion, and immune escape within the tumor microenvironment.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are ncRNAs considered promising for diagnostic, prognostic, and therapeutic uses?",{"text":121,"@type":113},"ncRNAs can regulate the PD-1/PD-L1 pathway and affect key transcription factors involved in tumor progression. Identifying regulatory ncRNAs and their target genes may support the development of new therapeutic interventions against brain cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354686,1790256449,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Iranian Journal of Basic Medical Sciences  \n[ijbms.mums.ac.ir](ijbms.mums.ac.ir)  \n\n| |  |  |  |\n| --- | --- | --- | --- |\n| Non-coding RNAs related to PD1/PD-L1 signaling with potential diagnostic, prognostic, and therapeutic value in the tumorigenesis of brain cancers\u003Cbr>Reihane Behnam-Rassouli 1, 2, Farzaneh Entezari 3, Majid Ghorbanzadeh 4, Ali Reyhani 5, Mohammadreza Nassiri 1, Fereshteh Golab 2, Farzad Rahmani 5, 6*\u003Cbr>1 Recombinant Proteins Research Group, The Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran\u003Cbr>2 Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran\u003Cbr>3 Department of Surgical and Diagnostic Integrated Sciences, University of Genova, Genova, Italy\u003Cbr>4 School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran\u003Cbr>5 Kashmar School of Medical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran\u003Cbr>6 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran |  |  |  |\n| A RT I C L E I N F O\u003Cbr>Article type:\u003Cbr>Review\u003Cbr>Article history:\u003Cbr>Received: Jan 25, 2026\u003Cbr>Accepted: May 18, 2026\u003Cbr>Keywords:\u003Cbr>Brain neoplasms Immune evasion MicroRNAs Non-coding RNAs PD-1/PD-L1 |  | \u003Cbr>A B ST R A CT\u003Cbr>Brain cancers are among the most aggressive malignancies associated with significant global morbidity and mortality. Cancer immunotherapy has emerged as a promising novel approach for the treatment of brain cancer through regulating the PD-1/PD-L1 signaling and disrupting tumor immune escape. Several targeted therapies have been developed to inhibit the PD-1/PD-L1 route, but reduced therapeutic responses and drug resistance remain a major challenge that needs to be addressed. Notably, non-coding RNAs (ncRNAs), which include microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs), exert crucial effects on cell proliferation, invasion, and immune escape in the tumor microenvironment (TME) . It has been shown that ncRNAs reduce tumor formation and progression by regulating the PD-1/PD-L1 pathway and by down-regulating key transcription factors, including NF-κB, JAK, and STAT. Therefore, identifying novel regulatory ncRNAs and their associated target genes offers promising opportunities for developing therapeutic interventions against brain cancer. This review highlights recent advances in understanding the regulatory role of ncRNAs on the PD-1/ PD-L1 pathway in brain cancer tumorigenesis. |  |\n| ► Please cite this article as:\u003Cbr>Behnam-Rassouli R, Entezari F, Ghorbanzadeh M, Reyhani A, Nassiri MR, Golab F, Rahmani F. Non-coding RNAs related to PD1/PD-L1 signaling with potential diagnostic, prognostic, and therapeutic value in the tumorigenesis of brain cancers. Iran J Basic Med Sci 2026; 29: 1174-1183. doi: [https://dx.doi.org/10.22038/ijbms.2026.94213.20304](https://dx.doi.org/10.22038/ijbms.2026.94213.20304) |  |  |  |\n| \u003Cbr>Introduction\u003Cbr>Brain tumors are among the most aggressive cancersand the leading cause of cancer-related death worldwide (1) . Despite recent advances in diagnostic and therapeutic methods, patients are often diagnosed at advanced stages, with a dismal prognosis and poor survival outcomes (2) . Emerging evidence suggests that brain cancer pathogenesis involves multiple cellular processes that facilitate tumor cell immune escape (3) . In this context, studies have shown that programmed cell death protein 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1), trigger immunosuppressive signaling pathways that enable cancer cells to evade immune surveillance (4) .\u003Cbr>PD-1 is a key inhibitory receptor induced on activated T cells, which functions as a central regulator of immune activation (5). Upon binding its ligands (PD-L1 or PD-L2), PD-1 recruits phosphatases like SHP2 to primarily attenuate CD28-mediated stimulatory signaling, thereby limiting the secondary signals required for full T-cell activation (6, 7) . This targeted inhibition ","cbCaidapXGx8rcUQ","https://ap.wps.com/l/cbCaidapXGx8rcUQ","pdf",493315,"English","# Introduction\n## PD-1 and PD-L1 in brain tumor immune escape\n## Roles of ncRNAs in regulating the PD-1/PD-L1 pathway","[{\"question\":\"How does PD-1/PD-L1 signaling contribute to immune evasion in brain cancer?\",\"answer\":\"PD-1 and its ligand PD-L1 initiate immunosuppressive pathways that help cancer cells avoid immune surveillance. PD-1 signaling dampens T-cell activation and can enhance tumor immune escape in the brain tumor microenvironment.\"},{\"question\":\"What types of non-coding RNAs are discussed in relation to PD-1/PD-L1?\",\"answer\":\"The review highlights microRNAs, circular RNAs, and long non-coding RNAs. These ncRNAs influence cell proliferation, invasion, and immune escape within the tumor microenvironment.\"},{\"question\":\"Why are ncRNAs considered promising for diagnostic, prognostic, and therapeutic uses?\",\"answer\":\"ncRNAs can regulate the PD-1/PD-L1 pathway and affect key transcription factors involved in tumor progression. Identifying regulatory ncRNAs and their target genes may support the development of new therapeutic interventions against brain cancer.\"}]","Non-coding RNAs related to PD1/PD-L1 signaling with potential diagnostic, prognostic, and therapeutic value in the tumorigenesis of brain cancers | PDF",1790113007,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5327a3f39a462c24c6239eb5918d42ce.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37344ef4d62805d055a9da203ee219b3.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b254d86f6bd5acb42d9d5222ff915f13.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a151df83913b64852381d5f6fe44dfe.webp",980,1385]